Author name: Leonardo Arias

In the United States, only 31.4 % of phase II/III clinical trials in oncology are successfully completed1. The causes of this dramatic economic and time-consuming loss are, among others, protocol design and patient recruitment challenges.

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical industry’s reputation amid mounting criticism.

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and shuttered businesses. Here are five biopharma players staying alive with differentiated candidates against the once promising immuno-oncology target.

  El interés por métodos innovadores que favorezcan el bienestar cotidiano ha impulsado el desarrollo de soluciones tecnológicas no invasivas, diseñadas para integrarse fácilmente en la rutina. Una de las propuestas que ha captado la atención en el & …

Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.

The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.

Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.  

The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.